Lamizil UNO solution 1% 4g

Description

Lamizil UNO Composition
Solution for external use, film-forming 1%, transparent or slightly opaque, viscous, from colorless to light yellow in color, with an ethanol odor. 1 g of terbinafine hydrochloride 11.25 mg, which corresponds to the content of terbinafine 10 mg.

Excipients: copolymer of acrylic acid and octylacrylamide (Dermacryl 79), medium chain triglycerides, hyprolose, ethanol 96%.

Clinical and pharmacological group

Antifungal drug for external use

Lamizil UNO pharmachologic effect

Antifungal drug for external use, allylamine derivative. Possesses a wide spectrum of antifungal activity. In small concentrations, terbinafine has a fungicidal effect against Trichophyton dermatophytes (including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton violaceum, Trichophyton tonsurans), Microsporum canis and Epidermophytonus fungi, mainly fungal fungus, albumin (Pityrosporum orbiculare or Malassezia furfur). Activity against yeast fungi, depending on their type, can be fungicidal or fungistatic.

Terbinafine specifically alters the early stage of sterol biosynthesis in fungi. This leads to a deficiency of ergosterol and to intracellular accumulation of squalene, which causes the death of the fungal cell. Terbinafine works by inhibiting the enzyme squalene epoxidase located on the cell membrane of the fungus. Squalene epoxidase is not associated with the cytochrome P450 system. Terbinafine does not affect the metabolism of hormones or other drugs.

Pharmacokinetics

After applying Lamisil Uno to the skin, the solution forms a transparent imperceptible film that remains on the skin for 72 hours. From the film, terbinafine quickly penetrates into the stratum corneum: 60 minutes after the procedure, 16-18% of the applied dose is found in the stratum corneum. The release of terbinafine is progressive, the active substance is present in the stratum corneum after 13 days at a concentration exceeding the minimum inhibitory concentration of terbinafine in vitro in relation to dermatophytes.

Systemic bioavailability is extremely low. When applied externally, the absorption of the drug is less than 5%. Lamisil Uno has a slight systemic effect.

The relapse rate after 3 months of drug use is low (no higher than 12.5%).

Lamizil UNO Indications

mycoses (dermatophytosis) of the feet (tinea pedis).
Dosage regimen

The drug is used externally, once.

For adults and adolescents over the age of 15 years, the film-forming solution Lamisil Uno is applied 1 time to both feet, even if the fungal infection is observed only on one foot. This ensures the destruction of fungi (dermatophytes), which may be located in areas of the foot where the lesions are not visually noticeable.

Before applying the drug, you should wash and dry your feet and hands. First, one foot is processed, then the other. Starting the procedure on the interdigital areas, apply a thin layer evenly between the toes and around their entire surface, as well as on the sole and lateral parts of the foot to a height of up to 1.5 cm.Use a sufficient amount of the drug to cover the required skin surface, usually 1/2 tubes for processing each foot.

The other foot should be treated in the same way, even if the skin on it looks healthy. Dry the solution for 1-2 minutes until a film is formed. After finishing the treatment of the feet, you need to wash your hands.

Do not reapply the drug to treated skin. Lamisil Uno should not be rubbed into the skin.

Side effect

Side effects are extremely rare, mild and short-term.

Systemic reactions: very rarely – allergic reactions (rash, redness, bullous dermatitis and urticaria).

Local reactions: rarely – dryness, irritation of the skin or a burning sensation on the treated area of ​​the skin.

Lamizil UNO Contraindications

hypersensitivity to terbinafine or to any of the inactive ingredients that make up Lamisil Uno solution 1% 4 g of the drug.
With caution, the drug should be prescribed for hepatic and / or renal failure, alcoholism, inhibition of bone marrow hematopoiesis, tumors, metabolic diseases, occlusive vascular diseases of the extremities, as well as children under 15 years of age (due to lack of sufficient clinical experience).